Evaluation of the effectiveness of topiramate in treating dependence of amphetamine and methamphetamine patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160417027437N2

Enrollment

Registered

2021-07-19

Start date

2021-07-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug abuse. F19

Interventions

Intervention 1: Intervention group: To treat amphetamine and methamphetamine dependence, topiramate tablets are started at a dose of 50 mg per day, the dose is increased weekly until the 12th week to

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: patients aged 18-55 years With amphetamine and methamphetamine use disorders

Exclusion criteria

Exclusion criteria: History of major psychiatric disorder existence of harmful thoughts to oneself and others history of receiving psychiatric medication during the last 3 months pregnant woman or breast feeding BMI less than 18

Design outcomes

Primary

Measure	Time frame
Intensity of dependence. Timepoint: Weeks 2, 4, 6, 8, 10 and 12 after the intervention. Method of measurement: McLellan Dependency Index Questionnaire.	—

Secondary

Measure	Time frame
Depression. Timepoint: Weeks 2, 4, 6, 8, 10 and 12 after the intervention. Method of measurement: Beck Depression Inventory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Ali Moghadam Sadegh

Ahvaz University of Medical Sciences

moghaddam.a@ajums.ac.ir+98 61 3374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026